Head-to-head comparison
Boston Medical Group vs Hims & Hers
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Boston Medical Group is an established medical group running a 12-week compounded GLP-1 weight-loss program.
From $199/mo (lowest dose rung) sema · Verified August 2026
Marked down on: The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
Desk Score
Mass-market app-first program with nationwide polish — tirzepatide pricing disclosure lags the ranking.
$199/mo sema
Marked down on: Tirzepatide pricing inconsistently disclosed
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Hims & Hers takes this head-to-head with the higher Desk Score, 79/100 (C+) against 67/100 (C) for Boston Medical Group. Boston Medical Group still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Boston Medical Group
67/100
C
Hims & Hers
79/100
C+
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Boston Medical Group | Hims & Hers |
|---|---|---|
| Semaglutide | From $199/molowest dose rung$199/mo (starting strength, rising with dose, compounded) | $199/mo$199/mo |
| Tirzepatide | Not listed on Boston Medical Group's site (checked August 2026) | Not listed on Hims & Hers's site |
| Coverage | 7 states | All 50 states |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | People who want a clinician-run 12-week program and can accept a price quoted as a range rather than a rate. | People who want a familiar consumer-brand app experience and don't need tirzepatide. |
| Desk Score | 67/100C | 79/100C+ |
The verdict
Desk pick — Hims & HersHims & Hers takes this head-to-head with the higher Desk Score, 79/100 (C+) against 67/100 (C) for Boston Medical Group. Boston Medical Group still holds its ground where its strengths line up with yours.
Choose Boston Medical Group if…
People who want a clinician-run 12-week program and can accept a price quoted as a range rather than a rate.
From $199/mo (lowest dose rung) sema · 7 states
Choose Hims & Hers if…
People who want a familiar consumer-brand app experience and don't need tirzepatide.
$199/mo sema · All 50 states
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Boston Medical Group · Hims & Hers.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- Boston Medical Group vs CoreAge Rx
- CoreAge Rx vs Hims & Hers
- Boston Medical Group vs HealthRX
- Hims & Hers vs Ondra Health
- Boston Medical Group vs Breeze Meds
- Hims & Hers vs Vaylen
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.